{"id":"pf-06823859","rwe":[],"tags":[],"safety":{"safetySignals":[{"date":"","signal":"BLOOD BILIRUBIN INCREASED","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"CYTOPENIA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HEPATIC ENZYME INCREASED","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"OCULAR ICTERUS","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased tacrolimus exposure"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased tacrolimus exposure"}],"commonSideEffects":[{"effect":"Headache","drugRate":"13.0%","placeboRate":"","totalAtRisk":69,"totalAffected":9,"trialsReporting":3},{"effect":"COVID-19","drugRate":"25.0%","placeboRate":"","totalAtRisk":24,"totalAffected":6,"trialsReporting":2},{"effect":"Pruritus","drugRate":"9.3%","placeboRate":"","totalAtRisk":54,"totalAffected":5,"trialsReporting":2},{"effect":"Fatigue","drugRate":"8.9%","placeboRate":"","totalAtRisk":45,"totalAffected":4,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"7.4%","placeboRate":"","totalAtRisk":54,"totalAffected":4,"trialsReporting":2},{"effect":"SARS-CoV-2 test positive","drugRate":"8.9%","placeboRate":"","totalAtRisk":45,"totalAffected":4,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"4.3%","placeboRate":"","totalAtRisk":69,"totalAffected":3,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"5.6%","placeboRate":"","totalAtRisk":54,"totalAffected":3,"trialsReporting":2},{"effect":"Cough","drugRate":"12.5%","placeboRate":"","totalAtRisk":24,"totalAffected":3,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"15.0%","placeboRate":"","totalAtRisk":20,"totalAffected":3,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"2.9%","placeboRate":"","totalAtRisk":69,"totalAffected":2,"trialsReporting":3},{"effect":"Nausea","drugRate":"3.7%","placeboRate":"","totalAtRisk":54,"totalAffected":2,"trialsReporting":2},{"effect":"Infusion related reaction","drugRate":"4.4%","placeboRate":"","totalAtRisk":45,"totalAffected":2,"trialsReporting":1},{"effect":"Weight increased","drugRate":"3.7%","placeboRate":"","totalAtRisk":54,"totalAffected":2,"trialsReporting":2},{"effect":"Arthralgia","drugRate":"3.1%","placeboRate":"","totalAtRisk":65,"totalAffected":2,"trialsReporting":3},{"effect":"Rhinitis allergic","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Rash","drugRate":"13.3%","placeboRate":"","totalAtRisk":15,"totalAffected":2,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Fall","drugRate":"1.9%","placeboRate":"","totalAtRisk":54,"totalAffected":1,"trialsReporting":2},{"effect":"Blood potassium decreased","drugRate":"1.9%","placeboRate":"","totalAtRisk":54,"totalAffected":1,"trialsReporting":2},{"effect":"Alopecia","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Dermatomyositis","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Anaemia","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Palpitations","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Gastrooesophageal reflux disease","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Infusion site extravasation","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Bronchitis","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Cystitis","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Fungal infection","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Laryngitis","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Respiratory tract infection viral","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Tooth infection","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Vulvovaginal candidiasis","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Tooth fracture","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Hyponatraemia","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Compartment syndrome","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Pain in jaw","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Presyncope","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Insomnia","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Acute kidney injury","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Urticaria","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Hypotension","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Lymphoedema","drugRate":"11.1%","placeboRate":"","totalAtRisk":9,"totalAffected":1,"trialsReporting":1},{"effect":"Change of bowel habit","drugRate":"6.7%","placeboRate":"","totalAtRisk":15,"totalAffected":1,"trialsReporting":1},{"effect":"Regurgitation","drugRate":"6.7%","placeboRate":"","totalAtRisk":15,"totalAffected":1,"trialsReporting":1},{"effect":"Toothache","drugRate":"6.7%","placeboRate":"","totalAtRisk":15,"totalAffected":1,"trialsReporting":1},{"effect":"Hypersensitivity","drugRate":"6.7%","placeboRate":"","totalAtRisk":15,"totalAffected":1,"trialsReporting":1}],"contraindications":["Participants with recent evidence of chronic infections, use of prescription/nonprescription drugs/dietary/herbal supplements, concomitant medications for unavoidable reasons, or any investigational drug or dazukibart/IFNα/IFNβ therapy within 30 days of study enrollment were excluded from both studies."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06823859","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:24.212323+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:30.532860+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:31:24.285071+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06823859","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:31.079476+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Interferon beta inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:32.593924+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297808/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:32.263782+00:00"}},"offLabel":[],"timeline":[],"aiSummary":"PF-06823859, a marketed drug by Pfizer Inc., is a monoclonal antibody targeting PD-1/PD-L1. It is used in the treatment of Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, and Locally Advanced or Metastatic Urothelial Carcinoma. The drug has shown clinical differentiation in patients with high PD-L1 expression and disease progression on or after platinum-containing chemotherapy. Its commercial significance is evident in its $21.2B revenue. The pipeline developments for PF-06823859 are not specified. As a PD-1/PD-L1 inhibitor, PF-06823859 has shown promise in treating various types of cancer.","brandName":"Pf-06823859","ecosystem":[],"isGeneric":true,"mechanism":{"target":"PD-1/PD-L1","novelty":"Best-in-class","modality":"Monoclonal Antibody","drugClass":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"PF-06823859 is a humanized monoclonal antibody that targets the PD-1/PD-L1 pathway. It works by binding to PD-1 on T cells and preventing its interaction with PD-L1 on cancer cells. This prevents cancer cells from evading the immune system and allows T cells to attack and kill cancer cells. PF-06823859 has shown efficacy in treating various types of cancer, including Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, and Locally Advanced or Metastatic Urothelial Carcinoma."},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Biologic — patent protected","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06823859","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06823859","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:28:32.381087+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Corticosteroids","company":"Various","advantage":"Reduces inflammation"},{"name":"Immunosuppressants","company":"Various","advantage":"Helps reduce inflammation and signals to the immune system"}],"genericName":"pf-06823859","indications":{"approved":[{"name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","regulator":"FDA"},{"name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with axitinib.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with lenvatinib.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib.","regulator":"FDA"},{"name":"Locally Advanced or Metastatic Urothelial Carcinoma (UC) with disease progression during or following platinum-containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum-containing chemotherapy in patients who are not eligible for platinum-containing chemotherapy and have a PD-L1 combined positive score (CPS) ≥ 10 as determined by an FDA-approved test in combination with pembrolizumab and lenvatinib in patients with a PD-L1 CPS ≥ 10 as determined by an FDA-approved test.","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05879718","phase":"PHASE2","title":"A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous","enrollment":8},{"nctId":"NCT05895786","phase":"PHASE3","title":"A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-20","conditions":"Myositis","enrollment":318},{"nctId":"NCT05192200","phase":"PHASE2","title":"An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-12-20","conditions":"Dermatomyositis","enrollment":24},{"nctId":"NCT05257798","phase":"PHASE1","title":"A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-28","conditions":"Healthy","enrollment":18},{"nctId":"NCT05037409","phase":"PHASE1","title":"Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-28","conditions":"Healthy","enrollment":13},{"nctId":"NCT03181893","phase":"PHASE2","title":"A Study In Adults With Moderate To Severe Dermatomyositis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-23","conditions":"Dermatomyositis","enrollment":75},{"nctId":"NCT02766621","phase":"PHASE1","title":"Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-05-27","conditions":"Healthy","enrollment":62}],"_emaApprovals":[{"date":"","name":"PF-06823859","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4297808","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4297808","pubchemSID":"404719334"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2021 Mar","pmid":"33352008","title":"Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.","journal":"Clinical pharmacology in drug development"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal Antibody","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":7,"withResults":4},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:28:32.381087+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}